Glaukos Corporation's stock surged 14.68% in pre-market trading on Thursday, extending gains from the previous post-market session.

The significant move follows the ophthalmic therapy firm's release of first-quarter 2026 financial results that substantially exceeded analyst expectations. The company reported an adjusted loss per share of $0.18, beating the consensus estimate for a $0.27 loss. Furthermore, net sales for the quarter jumped 41% year-over-year to $150.6 million, well above the estimated $136.9 million.

In a key positive development, management raised its full-year 2026 net sales guidance to a range of $620 million to $635 million, up from the previous forecast of $600 million to $620 million. The strong performance was driven by products iDose TR and Epioxa, with the glaucoma segment showing particularly robust growth. The positive earnings report prompted multiple analyst firms, including JP Morgan, BTIG, Wells Fargo, Mizuho, and Stifel, to raise their price targets on the stock.